- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Clarivate Names Highly Cited Researcher 2022 Designations
Nearly 7,000 researchers from across the globe received designations.
Clarivate Plc revealed its 2022 list of Highly Cited Researchers–individuals at universities, research institutes, and commercial organizations who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research. The methodology draws on data from the Web of Science™ citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.
ISI analysts have awarded Highly Cited Researcher 2022 designations to 6,938 researchers from across the globe who demonstrated significant influence in their chosen field or fields over the last decade. The list spans 69 countries or regions and is spread across a diverse range of research fields in the sciences and social sciences.
Read more about this story here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
